Nov 30, 2022 / 01:30PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
All right. Morning, everybody. Thanks so much for joining us. I'm Matt O'Brien. I'm a med tech analyst here at Piper. I'm really excited to have the Dexcom team with us today. From the company is Matt Dolan. He's the Executive Vice President, Corporate Strategy and Business Development; and then Sean as well -- Christensen, who's Head of IR, and then I think he's just got a new FP&A rule as well. So thanks for making the Cross-country trip over. I really do appreciate it.
Matthew Dolan - DexCom, Inc. - EVP of Strategy, Corporate Development & Dexcom Labs
Thanks for having us. It's good to be here in person again, and here this time of the year, it's beautiful.
Questions and Answers:
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research AnalystYes, I couldn't be more excited to be in person. 100% agree with that. So let me get